---
id: COVID-19_107
category: organisms
tags: [COVID-19, SARS-CoV-2, remdesivir, nirmatrelvir-ritonavir, dexamethasone]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## COVID-19 (SARS-CoV-2)

**Q:** What are the clinical features, risk stratification, and evidence-based treatments for COVID-19 including antivirals and immunomodulators?

**A:**

## OVERVIEW

**Virus:** SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)

**Transmission:** Respiratory droplets, aerosols

**Incubation:** 2-14 days (median 5 days)

---

## CLINICAL FEATURES

**Spectrum:**
- **Asymptomatic** (20-40%)
- **Mild-Moderate:** Fever, cough, fatigue, myalgias, loss of taste/smell
- **Severe:** Dyspnea, hypoxemia (SpO2 <94%)
- **Critical:** ARDS, shock, multiorgan failure

**Complications:**
- **Acute respiratory failure** (ARDS)
- **Thromboembolism** (PE, DVT, stroke)
- **Myocarditis**
- **Acute kidney injury**
- **Post-COVID syndrome** ("long COVID")

---

## RISK FACTORS FOR SEVERE COVID-19

- **Age ≥65 years**
- **Immunocompromised**
- **Obesity (BMI ≥30)**
- **Diabetes**
- **Chronic lung/heart/kidney/liver disease**
- **Unvaccinated**

---

## TREATMENT

### **Mild-Moderate COVID-19 (Non-Hospitalized, High-Risk):**

**Antivirals (Start Within 5-7 Days of Symptom Onset):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Nirmatrelvir-ritonavir (Paxlovid)** | **300 mg nirmatrelvir + 100 mg ritonavir PO BID** | **5 days** |
| **Remdesivir** | **200 mg IV day 1 → 100 mg IV daily** | **3 days** |

**Key Point:** **Paxlovid = preferred** (oral, reduces hospitalization by ~90%)

**Contraindications (Paxlovid):**
- **Severe renal/hepatic impairment**
- **Drug interactions** (ritonavir CYP3A4 inhibitor - check interactions)

---

### **Hospitalized COVID-19:**

**Oxygen Support:**
- **Supplemental O2** if SpO2 <92%
- **High-flow nasal cannula, mechanical ventilation** (if severe hypoxemia)

**Antivirals:**

| **Agent** | **Dosing** | **Indication** |
|-----------|------------|----------------|
| **Remdesivir** | **200 mg IV day 1 → 100 mg IV daily** | **5 days** (or 10 days if immunocompromised) |

**Immunomodulators:**

| **Agent** | **Dosing** | **Indication** |
|-----------|------------|----------------|
| **Dexamethasone** | **6 mg PO/IV daily** | **10 days** (or until discharge)<br>**ONLY if requiring supplemental O2** |
| **Tocilizumab (IL-6 inhibitor)** | **8 mg/kg IV x 1 dose** (max 800 mg) | If rapidly escalating O2 needs + CRP ≥75 mg/L |
| **Baricitinib (JAK inhibitor)** | **4 mg PO daily x 14 days** | Alternative to tocilizumab |

**Key Point:** **Dexamethasone = standard** for hospitalized patients requiring O2 (reduces mortality by ~30%)

**Anticoagulation:**
- **Prophylactic LMWH/heparin** (all hospitalized patients unless contraindicated)
- **Therapeutic anticoagulation:** If thrombosis confirmed

---

### **Post-COVID Syndrome ("Long COVID"):**

**Definition:** Symptoms persisting >4 weeks after acute infection

**Common Symptoms:**
- **Fatigue, dyspnea, brain fog**
- **Post-exertional malaise**
- **Dysautonomia** (POTS)

**Treatment:** Symptomatic, rehabilitation

---

**Key Clinical Pearls:**
- **Paxlovid reduces hospitalization ~90%** (high-risk, mild-moderate COVID-19)
- **Dexamethasone ONLY if requiring O2** (harmful if no hypoxemia)
- **Start antivirals within 5-7 days** of symptom onset

**Media:** None

**Sources:** [NIH COVID-19 Treatment Guidelines 2024]
